Onco Cell Therapy Summit USA 2022

OCTS USA 2022 (June 29-30)

Delivering Safe and Effective Adoptive Cell Therapy Products to Clinical Promise, Commercial Scale Manufacturing and Patients

Download 2022 Agenda

Why Attend

The Onco Cell Therapy Summit (OCTS) is the only industry-led meeting covering the full range of autologous and allogeneic cell product advancements. A four-tracked agenda, featuring pioneering biopharma, academia, and solution-providers, will address all innovative MoA, manufacturing challenges, and clinical progress of CAR T, TCR T, TILs, Macrophages, and NK cells in treating haematological and solid tumors. Expect to hear from CXOs, VPs, R&D and Process Developers on the opportunities generated from recent clinical and technological data, and how they are tackling the most pressing industry challenges to get effective treatments to patients.

To facilitate connections between relevant peers and spark solution-led discussions, the summit is broken down into four streamlined tracks – Pre-clinical & Translational Research, Clinical, Manufacturing and Logistics & Market Access. You will be able to step into interactive discussions and engaging presentations on the key product development questions:

1. How to expand the durability of response by targeting antigen heterogeneity, optimized affinity, specificity and reduce cell exhaustion in the TME?
2. How can genome editing technologies lead to successful clinical applications?
3. What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies?
4. How to make the transition from proven research-scale to production-scale through a robust manufacturing platform?
5. Where to direct resources to build resilience and create a ‘vein-to-vein’ and IPSC-derived, patient-centric cell therapy supply chain?

OCTS will enable your teams to identify the rationale and progress in developing cell engineering platforms to generate a robust pipeline of potent, safe therapies. There will be a 360-view of the ongoing phase 1 / 2 trials, building out cGMP manufacturing capabilities through automation and in-process analytics, recalibrating supply chains to build resilience in a dynamic research field and ensuring novel therapies address unmet clinical need.

WHO WILL BE THERE

Network with industry experts from:

  • Senior-level leaders from biotech and representatives from big pharma
  • Academic experts in cell therapy
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers – CROs, CDMOs, consultants, logistics companies and more

Last year's attendees included:

Confirmed 2022 Speakers

 

John Langowski

VP, Cell Biology
Kite Pharma

John Langowski

VP, Cell Biology
Kite Pharma

John Langowski

VP, Cell Biology
Kite Pharma
 

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA

Peter Bross

Chief, Oncology Branch, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research
FDA
 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Crystal L Mackall MD

Director
Stanford Center for Cancer Cell Therapy

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine 

Director, Stanford Center for Cancer Cell Therapy 

Director, Parker Institute for Cancer Immunotherapy at Stanford 

Co-Executive Director, Stanford Laboratory for Cell and Gene Medicine 

Associate Director, Stanford Cancer Institute 

 

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics

Arun Balakumaran

SVP, Head of Clinical Development
Allogene Therapeutics
 

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis

Vered Caplan

CEO
Orgenesis
 

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics

Birgit Schultes

Senior VP, Head of Cell Therapies
Intellia Therapeutics
 

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA.

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel

SVP, Head of Manufacturing
Sana Biotechnology

Snehal Patel is the Global Head and Vice President for Cell Therapy Manufacturing for Bristol Myers Squibb (BMS). He leads the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including the two cell therapies recently launched in 2021 by BMS. Overseeing three state-of-the-art production facilities, Snehal is also closely involved in planning, development and construction of two additional facilities to continue expanding BMS’ global footprint. In addition, he has served as Site Head for Cell Therapy Manufacturing and is based in Seattle, WA. He started at BMS via the Juno Therapeutics acquisition in February 2018.

Prior to joining BMS, Snehal worked at Genentech/Roche for ~18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.

Snehal has a breadth of knowledge and experience including leadership roles in Technical Operations, Technology, Training, and Quality Assurance in Biologics, Small Molecules, and Cell Therapy. He is routinely sought out for his technical expertise, as well as his ability to collaborate and influence. He is a dynamic leader where he focuses on Inspirational Leadership and Development of his team.

 

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research

Serena De Vita

Clinical Program Leader & Senior Director
Novartis Institutes for BioMedical Research
 

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.

Debora Barton, MD

Chief Medical Officer
Carisma Therapeutics Inc.
 

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio

Kate Rochlin

Chief Operating Officer
In8Bio
 

Christopher Pastorello

Director, Head of GMP Operations
Century

Christopher Pastorello

Director, Head of GMP Operations
Century

Christopher Pastorello

Director, Head of GMP Operations
Century
 

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine

Robbie Majzner

Assistant Professor, Pediatrics
Stanford University School of Medicine
 

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma

Eric Halioua

CEO
PDC*Line pharma
 

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka

Cheng Liu

Founder, President and CEO
Eureka
 

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma

Carnley Norman

Vice President of Global Manufacturing Sciences and Technology (MSAT)
Kite Pharma
 

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics

Austin Boesch

Director, Head of Protein Sciences
Tidal Therapeutics
 

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey

Christian Hinrichs

Chief of the Section of Cancer Immunotherapy
Rutgers Cancer Institute of New Jersey
 

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School

Stefanie Bailey

Research Fellow
Massachusetts General Hospital and Harvard Medical School
 

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm

Michael Leek

Co-founder and Executive Chairman
TC Biopharm
 

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics

Paul Rennert

Acting CEO, President, CSO
Aleta Biotherapeutics
 

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis

Guanglin Yu

Senior Expert Science & Technology
Novartis
 

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania

Adham Bear

Instructor of Medicine
Division of Hematology and Oncology, Hospital of the University of Pennsylvania
 

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune

Moonsoo Jin

Professor of Biomedical Engineering in Radiology, Radiology; Co-founder
Weill Cornell Medical College; Affyimmune
 

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia

Mark Yarmarkovich

Senior Scientist
Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
 

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center

Jorge Mansilla-Soto

Senior Research Scientist
The Michel Sadelain Lab, Sloan Kettering Insititute, Memorial Sloan Kettering Cancer Center
 

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell

John Lu

President and CEO
HebeCell
 

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics

Branden Moriarity

Chief Innovation Officer
Luminary Therapeutics
 

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics

Jan ter Meulen

CSO
Obsidian Therapeutics
 

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics

Gavin MacBeath

CSO
Tscan Therapeutics
 

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio

Alba Gonzalez

Associate Director R&D
Senti Bio
 

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics

Amanda Conerty

Executive Director of Analytical, Process development and Manufacturing
Artiva Biotherapeutics
 

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics

David Brochu

CTO
Autolus Therapeutics
 

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School

Jeffrey S Miller

Professor of Medicine, Division of Hematology, Oncology and Transplantation
University of Minnesota Medical School
 

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics

Jennifer Buell

President and CEO
MiNK Therapeutics
 

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care

Lucas de Breed

Founder
August Care
 

Matthew Li

Director
Tome Biosciences

Matthew Li

Director
Tome Biosciences

Matthew Li

Director
Tome Biosciences
 

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb

Gail Turner

Senior Principal Scientist, Preclinical Sciences, Immune Oncology and Cell Therapy Thematic Research Center
Bristol Myers Squibb
 

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross

Melissa Sebok

Executive Director – Product, Client & Business Development, Direct Patient Care & Emerging Offerings
American Red Cross
 

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB

Reagan Jarvis

CEO
Anocca AB
 

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus

Markus Gruell

Site Quality Head, Qualified Person
Autolus
 

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics

Robert Tighe

Vice President, Research
TCR2 Therapeutics
 

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring

Christina Bailey

Director, Cell and Gene Therapy, NanoString Technologies
Nanostring
 

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics

Laura Johnson

Chief Scientific Officer
Verismo Therapeutics
 

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis

Steven Doares

SVP & Site Head, US Manufacturing
Cellectis
 

Pete Smith

CEO
Myrio Tx

Pete Smith

CEO
Myrio Tx

Pete Smith

CEO
Myrio Tx
 

Breanna DiAndreth

Scientist II
A2 Biotherapeutics

Breanna DiAndreth

Scientist II
A2 Biotherapeutics

Breanna DiAndreth

Scientist II
A2 Biotherapeutics
 

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences

Subhadra Jayaraman

Senior Scientist I
Mammoth Biosciences
 

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia is T-knife‘s Director TCR discovery and is one of its founding scientists. She studied Human Biology in Marburg and Toowoomba (Australia) and obtained a doctor’s degree in tumor immunology from the Free University of Berlin followed by a PostDoc at the Max Delbrück Center for Molecular Medicine in Berlin. For the last 10 years Lucia has studied T cell receptors and their application in the treatment of cancer. At T-knife Lucia oversees the early development and characterization of T cell receptors using T-knife‘s proprietary myT platform.

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia Poncette

Director, TCR Discovery
T-Knife Therapeutics

Lucia is T-knife‘s Director TCR discovery and is one of its founding scientists. She studied Human Biology in Marburg and Toowoomba (Australia) and obtained a doctor’s degree in tumor immunology from the Free University of Berlin followed by a PostDoc at the Max Delbrück Center for Molecular Medicine in Berlin. For the last 10 years Lucia has studied T cell receptors and their application in the treatment of cancer. At T-knife Lucia oversees the early development and characterization of T cell receptors using T-knife‘s proprietary myT platform.

 

Stefania Gobessi

Director, Discovery
Gadeta BV

Stefania Gobessi

Director, Discovery
Gadeta BV

Stefania Gobessi

Director, Discovery
Gadeta BV
 

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics

Raymond Luke

Director, Manufacturing Science and Technology
Verismo Therapeutics
 

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.

Vineet Kacker

Managing Director
APCER Life Sciences, Inc.
 

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx

Ashish Kothari

VP, Clinical Development, Cell Transplant Therapy
CareDx
 

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures

Nissim Darvish

Venture Partner, OrbriMed & Managing General Partner
MeOhr Ventures
 

David Moskowitz

Principal
8VC

David Moskowitz

Principal
8VC

David Moskowitz

Principal
8VC
 

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital

Ansbert Gadicke

Managing Director, MPM Capital – Managing Partner
BioImpact Capital
 

Philip Lee

CTO & Co-founder
Senti Biosciences

Philip Lee

CTO & Co-founder
Senti Biosciences

Philip Lee

CTO & Co-founder
Senti Biosciences
 

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio

Jennifer McDevitt

VP, Clinical Sciences
ArsenalBio
 

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.

David Ferrick

PhD., Chief Scientific Officer
Axion Biosystems Inc.
 

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma

Brian Newsom

Senior Director of Business Development for Cell Therapy
KBI Biopharma
 

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Jens Eberlein

Technical Lead, Immuno-Oncology
LUMICKS

Get The Agenda

What's New For 2022?

  • Dedicated ‘Preclinical and Translational Science’ track focused on ‘Developing Versatile Cell Therapy Engineering Platforms, with specific talks on targeting antigen heterogeneity (Talks from A2 Biotherapeutics, T-Knife Therapeutics, Enara Bio, Eureka Therapeutics), improving cell therapy durability (Talks from Aleta Biotherapeutics, TCR2 Therapeutics), harnessing innate immune cells (Talks from Senti Bio, Caribou Biosciences).
  • Specific talks and discussion on gene modification strategies for next-generation cell therapy products (Talks from Intellia Therapeutics, Allogene Therapeutics, Mammoth Biosciences, In8bio).
  • What clinical progress is being made in 'off-the-shelf' allogeneic cell therapies (Talks from Rutgers Cancer Institute of New Jersey, MiNK Therapeutics, PDC*Line Pharma).
  • Focused track on developing manufacturing capabilities on a clinical scale and scaling into the commercial setting (Talks from TC Biopharm, Century Therapeutics, Bristol Myers Squibb, Kite Pharma).
  • As more biotechs look beyond clinical development and plan for future market access strategies, OCTS 2022 now has dedicated sessions addressing this subject (Talks from Bayer Pharmaceuticals, Instil Bio, August Care).


Download The 2022 Agenda

Partners

Platinum Partner

Gold Partners

Event Partners

Exhibitors

Media Partners

Non-Profit Partner

PARTNER WITH US

Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Ryan Sanderson, Commercial Partnerships Director; [email protected].

DOWNLOAD THE SPONSORSHIP PROSPECTUS HERE.

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager; [email protected]

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, May 28, 2022 to Thursday, June 30, 2022
Tier 1 - Academics
$1499
Standard Pricing
Saturday, May 28, 2022 to Thursday, June 30, 2022
Tier 2 - Biotech & Pharma
$2699
Standard Pricing
Saturday, May 28, 2022 to Thursday, June 30, 2022
Tier 3 - Service Provider
$3699
Standard Pricing
Preparing registration...

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 5% Off
Book a Team of 5+ - Save an Additional 10% Off
Book a Team of 10+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Resources

Download Resource

OCTS Innovation Awards 2022

The OCTS Innovation Awards, part of the Onco Cell Therapy Summit in Boston (June 29-30), are a fantastic opportunity to recognise leaders and pioneers who have been instrumental to innovation in an incredibly exciting year for the cell therapy industry.

The awards are a people’s choice vote for excellence in cell therapy. We will open up nominations and voting to a universal network of industry leaders.

If you, or someone you know, has spearheaded innovation in cell therapy, or has been pivotal in the implementation of in-house innovation, we want to celebrate your achievements and empower you for future success!

CATEGORIES FOR 2022:

Solution Provider of the Year

For organisations who have demonstrated passion, skill, and expertise in developing a world class solution/service in cell and gene therapy.

Nominate a business

Biotech Innovator of the Year

Celebrating the outstanding contribution of an individual who is driving meaningful change or spearheading innovative projects.

Nominate an individual

Venue

Hynes Convention Center

900 Boylston St, Boston, MA 02115, United States

To view local hotels near to the event venue please click here: https://hotelmap.com/hotels/MLSLZ

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us